HRG and breast carcinoma: We present evidence that FASN is a key enabler for endocrine resistance in HRG+/HER2− breast cancer and highlight the therapeutic potential of FASN inhibitors for the treatment of endocrine therapy-resistant luminal B-like breast cancer.